These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38161697)

  • 1. Ansofaxine hydrochloride inhibits tumor growth and enhances Anti-TNFR2 in murine colon cancer model.
    Jing Q; Wan Q; Nie Y; Luo J; Zhang X; Zhu L; Gui H; Li L; Wang C; Chen S; Wang M; Yuan H; Lv H; Pan R; Jing Q; Nie Y
    Front Pharmacol; 2023; 14():1286061. PubMed ID: 38161697
    [No Abstract]   [Full Text] [Related]  

  • 2. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
    Chen Y; Jia M; Wang S; Xu S; He N
    Front Immunol; 2022; 13():835690. PubMed ID: 35251028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor receptor 2 promotes endothelial cell-mediated suppression of CD8+ T cells through tuning glycolysis in chemoresistance of breast cancer.
    Hu Y; Lou X; Zhang K; Pan L; Bai Y; Wang L; Wang M; Yan Y; Wan J; Yao X; Duan X; Ni C; Qin Z
    J Transl Med; 2024 Jul; 22(1):672. PubMed ID: 39033271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
    Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
    He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
    Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
    Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
    Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.
    Nie Y; He J; Shirota H; Trivett AL; Yang D; Klinman DM; Oppenheim JJ; Chen X
    Sci Signal; 2018 Jan; 11(511):. PubMed ID: 29295954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer.
    Jiang M; Liu J; Yang D; Tross D; Li P; Chen F; Alam MM; Faustman DL; Oppenheim JJ; Chen X
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108345. PubMed ID: 34794079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNFR2 deficiency impairs the growth of mouse colon cancer.
    Li P; Yang Y; Yang X; Wang Y; Chou CK; Jiang M; Zheng J; Chen F; Chen X
    Int J Biol Sci; 2023; 19(4):1024-1035. PubMed ID: 36923938
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation.
    Moatti A; Debesset A; Pilon C; Beldi-Ferchiou A; Leclerc M; Redjoul R; Charlotte F; To NH; Bak A; Belkacemi Y; Salomon BL; Issa F; Michonneau D; Maury S; Cohen JL; Thiolat A
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
    Williams GS; Mistry B; Guillard S; Ulrichsen JC; Sandercock AM; Wang J; González-Muñoz A; Parmentier J; Black C; Soden J; Freeth J; Jovanović J; Leyland R; Al-Lamki RS; Leishman AJ; Rust SJ; Stewart R; Jermutus L; Bradley JR; Bedian V; Valge-Archer V; Minter R; Wilkinson RW
    Oncotarget; 2016 Oct; 7(42):68278-68291. PubMed ID: 27626702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy Targeting CCR8+ Regulatory T Cells Induces Antitumor Effects via Dramatic Changes to the Intratumor CD8+ T Cell Profile.
    Ueyama A; Nogami W; Nashiki K; Haruna M; Miwa H; Hagiwara M; Nagira M; Wada H; Nagira Y
    J Immunol; 2023 Aug; 211(4):673-682. PubMed ID: 37350632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors.
    Baram T; Erlichman N; Dadiani M; Balint-Lahat N; Pavlovski A; Meshel T; Morzaev-Sulzbach D; Gal-Yam EN; Barshack I; Ben-Baruch A
    Cells; 2021 Jun; 10(6):. PubMed ID: 34201054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TNFR2 Antibody-Conjugated PLGA Nanoparticles for Targeted Delivery of Adriamycin in Mouse Colon Cancer.
    Li P; Yang Y; Wang Y; Zheng J; Chen F; Jiang M; Chou CK; Cong W; Li Z; Chen X
    Research (Wash D C); 2024; 7():0444. PubMed ID: 39247806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
    Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
    Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
    Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
    Front Immunol; 2018; 9():583. PubMed ID: 29623079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Necrosis Factor Receptor 2 Restricts the Pathogenicity of CD8(+) T Cells in Mice With Colitis.
    Punit S; Dubé PE; Liu CY; Girish N; Washington MK; Polk DB
    Gastroenterology; 2015 Oct; 149(4):993-1005.e2. PubMed ID: 26072395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-mediated targeting of TNFR2 activates CD8
    Tam EM; Fulton RB; Sampson JF; Muda M; Camblin A; Richards J; Koshkaryev A; Tang J; Kurella V; Jiao Y; Xu L; Zhang K; Kohli N; Luus L; Hutto E; Kumar S; Lulo J; Paragas V; Wong C; Suchy J; Grabow S; Dugast AS; Zhang H; Depis F; Feau S; Jakubowski A; Qiao W; Craig G; Razlog M; Qiu J; Zhou Y; Marks JD; Croft M; Drummond DC; Raue A
    Sci Transl Med; 2019 Oct; 11(512):. PubMed ID: 31578241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.